FDA warned BioMD Plus LLC that its CBD and Delta-8 THC products are unapproved drugs and its Delta-8 gummies contain an unsafe food additive.
What happened
FDA reviewed BioMD Plus's website in February 2022 and its social media accounts, which direct consumers to the website to buy products. FDA found claims that CBD and Delta-8 THC products treat conditions such as anxiety, depression, pain, schizophrenia, dementia, Crohn's disease, and cancer, plus similar claims for a pet CBD oil. FDA also found Delta-8 THC in gummies, a conventional food, with no approved food-additive use.
What FDA found
The human CBD and Delta-8 THC products are unapproved new drugs because website and social media claims show they are intended to treat disease, and no FDA-approved application is in effect.
FD&C Act sections 505(a) and 301(d), 21 U.S.C. 355(a) and 331(d)The human CBD and Delta-8 THC products are misbranded because their labeling lacks adequate directions for a layperson to use them safely for the claimed conditions.
FD&C Act section 502(f)(1), 21 U.S.C. 352(f)(1)Natural Pet CBD Oil is an unapproved new animal drug and is unsafe and adulterated under the animal drug provisions.
FD&C Act sections 512(a) and 501(a)(5), 21 U.S.C. 360b(a) and 351(a)(5)Delta-8 THC gummies are adulterated food because Delta-8 THC is an unsafe food additive that is not approved for food use and is not generally recognized as safe.
FD&C Act section 402(a)(2)(C)(i), 21 U.S.C. 342(a)(2)(C)(i)CBD capsules and gummies cannot be dietary supplements because FDA has concluded CBD is excluded from the dietary supplement definition.
FD&C Act sections 201(ff)(3)(B)(i) and (ii), 21 U.S.C. 321(ff)(3)(B)(i) and (ii)Even as a nonprescription drug, CBD Pain Relief Cream would need an approved new drug application; CBD is not in an OTC monograph and no CBD-containing drug has met requirements for legal nonprescription marketing.
FD&C Act section 505G; 21 CFR 330.1(e)
What FDA wants
FDA tells BioMD Plus to stop introducing or delivering the products into interstate commerce and to correct its claims and labeling. The company must respond in writing within 15 working days describing corrections and steps to prevent recurrence.
Who should pay attention
- CBD and Delta-8 THC brands and retailers
- contract manufacturers and labelers of hemp-derived products
- pet supplement sellers making therapeutic claims
This is a summary. Read the original letter on fda.gov.